UAE Hosts Landmark GCC Conference on Military Fitness and Readiness
The UAE Ministry of Defence today inaugurated the Scientific Conference on Physical Readiness of Land Forces in GCC Countries at Erth Hotel, Abu Dhabi.
The event drew senior military officials, experts, and specialists from across the region, marking a key step in strengthening regional cooperation in military fitness and operational preparedness.
Brigadier General Staff Mohammed Khamis Al Hassani, Deputy Commander of the UAE Land Forces, led the opening ceremony alongside top defence officials, highlighting the UAE's commitment to enhancing collective defence capabilities across Gulf Cooperation Council (GCC) states.
Running until April 25, the conference focuses on unifying strategies for combat and fitness readiness. Core topics include environmental challenges in training, injury prevention, mental health, and the integration of artificial intelligence in physical rehabilitation. Attendees will also examine successful case studies and best practices in regional military training.
Specialised workshops and lectures aim to boost efficiency in physical assessments and deepen joint cooperation among GCC member states. The goal is to develop shared frameworks that align with the strategic defence objectives of the region's land forces.
The event reflects a growing emphasis on innovation, collaboration, and resilience in the evolving landscape of regional security.
News Source: Emirates News Agency
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Arabian Business
17 hours ago
- Arabian Business
Inside Insilico's bid to create the UAE's first homegrown cancer drug
Clinical-stage biotech company Insilico Medicine recently announced it will attempt to discover the first novel cancer drug developed entirely in the United Arab Emirates with just four scientists and its proprietary AI platform to complete work that traditionally takes hundreds of researchers and years of effort. The Abu Dhabi-based team aims to identify promising cancer targets, design new molecules, and prepare a complete preclinical data package within 18 months—a process that typically takes pharmaceutical companies three to five years and costs hundreds of millions of dollars. 'Our Masdar City centre already hosts around 60 AI and biotech specialists. By tasking four of them with a complete end-to-end discovery run, we aim to prove that any GCC nation equipped with cloud compute, wet-lab automation and local talent can create world-class therapeutics,' Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine, told Arabian Business. The initiative represents both a scientific experiment and a geopolitical statement as it has the potential to transform the Middle East's role in global pharmaceutical development while challenging fundamental assumptions about where and how drug discovery can occur in the AI era. Four scientists, one AI The team consists of two computational chemists, one medicinal chemist, and one translational biologist – a deliberately lean operation working alongside Insilico's proprietary AI system, They are targeting what the company describes as 'medium-novelty and genetically validated synthetic-lethality targets' for solid tumours –essentially, seeking ways to kill cancer cells by exploiting specific genetic vulnerabilities. In pharmaceutical terms, the team is working at breakneck speed. Their roadmap calls for finalising a biological target by Q3 2025, generating promising molecular structures in under 30 days, and completing the entire preclinical package within 18 months. Traditional drug discovery typically takes three to five years just to reach the preclinical stage. 'Humans still design strategy and verify results, but AI handles the brute-force search, learns from every experiment in real time, and steers us away from dead ends,' explained Zhavoronkov. His description evokes a chess grandmaster working with a silicon partner—humans providing intuition and judgment, the machine crunching through billions of possibilities. Why the UAE? The choice of Abu Dhabi might seem puzzling at first. The UAE has invested heavily in healthcare infrastructure, but it remains far from established biotech hubs like Boston, San Francisco, or Cambridge. For Zhavoronkov, that's precisely the point. 'The reason we chose the UAE is because we already have a base there,' he said, referring to the AI Research and Development Centre that Insilico opened in Masdar City in 2023 with support from the Abu Dhabi Investment Office. 'UAE scientists helped discover a drug but they never tried to take full control over the drug discovery program.' This initiative – which Zhavoronkov is careful to note is self-funded by Insilico, not UAE government money – is as much about proving a concept as it is about discovering a specific drug. If a small team in Abu Dhabi can successfully identify a viable cancer treatment, it suggests that any country with sufficient computing resources and a small cadre of specialists could potentially develop life-saving medications. 'Not just lucky' Insilico's approach builds on research dating back to 2016, when the company published one of the first papers describing how generative adversarial networks (GANs) – the same AI architecture later used in image generators like DALL-E – could design novel molecules. The biotech landscape is littered with AI companies that promised to revolutionise drug discovery but delivered little. Zhavoronkov seems acutely aware of this skepticism. 'Since 2021 we have nominated 22 development candidates, advanced 10 into the clinic, completed four Phase I trials and a Phase IIa – without a single clinical failure,' he said. 'Those numbers convert skepticism into evidence.' Asked why Insilico has succeeded where others have not, Zhavoronkov pointed to four specific factors: 'Pristine, well-curated data – quantity without quality is noise; a closed experimental loop where every prediction is rapidly tested in-house and fed back to the models; deep integration of AI engineers, biologists and chemists under one roof… and many experimentally-validated AI models that we know worked in real world.' In an industry where approximately 90 per cent of drug candidates fail during development, Insilico's lead drug, Rentosertib, recently showed positive results in a Phase IIa trial for idiopathic pulmonary fibrosis (a serious lung disease that causes scarring of the lungs). The company reported that Rentosertib demonstrated favourable safety and tolerability across all dose levels, with promising early efficacy signals after just 12 weeks of treatment. In January 2025, Nature Biotechnology published a paper detailing Rentosertib's journey from AI algorithms to clinical trials – the first comprehensive account of an AI-discovered and AI-designed drug from initial concept to human testing. The company is already planning to expand across the Gulf region. Insilico recently signed a Memorandum of Understanding with Saudi Arabia's Ministry of Investment and plans to establish an operation in Riyadh by 2026, with partial funding from Aramco's Prosperity7 Ventures. The company is also in discussions with Qatar, Kuwait, Bahrain, and Oman about potential expansion. 'If the pilot hits its timelines, we will deploy identical micro-teams across the region, accelerating the sovereign drug-discovery capabilities where it matters most,' Zhavoronkov said. The bigger picture Beyond regional implications, Insilico's experiment touches on a profound question: does drug discovery still need massive teams, extensive physical infrastructure, and geographical proximity to traditional biotech clusters? 'The goal is to have multiple AI-originated drugs approved and on pharmacy shelves, with a steady stream of new candidates entering the clinic every year,' he said. '[For Insilico Medicine,] success looks like regulators, payers and physicians treating AI-designed medicines as the norm – much like jetliners are now designed in silico.' Alex Aliper, Co-Founder and President of Insilico Medicine, framed the effort in economic terms, suggesting that channelling the Gulf's 'deep technology' investments into 'life-saving medicines offers the fastest way to diversify economies and extend healthy longevity' in the region.
Khaleej Times
5 days ago
- Khaleej Times
AI hearing aid mimics human brain with 80 million real-time sound adjustments per hour
This Better Hearing Month, Starkey MEA is shining a spotlight on its most intelligent hearing solution to date — Edge AI — as part of an ongoing drive to promote hearing health awareness across the Middle East. Designed to replicate how the human brain processes sound, Edge AI performs up to 80 million personalised hearing adjustments per hour, helping users stay connected, confident, and comfortable in any environment. At the core of Edge AI is Starkey's groundbreaking G2 Neuro Processor, which boasts six times more transistors, ten times more memory, and four times faster processing than its predecessor. This advanced chip enables the device to automatically adapt to complex listening environments — whether it's a family majlis in the UAE, a bustling street in Jeddah, or a shopping mall in Kuwait City — ensuring seamless auditory clarity in real time. 'Edge AI isn't just a hearing aid — it's a technological breakthrough designed for real life,' said Giscard Bechara, Regional Director, MEA, Starkey Laboratories Inc. 'It's already changing lives across the GCC and wider region. And with May being Better Hearing Month, we want to remind the public that better hearing starts with a simple, preventive check-up. Early diagnosis makes all the difference.' Edge AI is equipped with features that enhance the user experience across connectivity, wellness, and convenience. These include Bluetooth LE Audio for seamless, energy-efficient streaming, Auracast™ broadcast capability, and a 60% smaller StarLink Edge TV Streamer for direct television audio. Select waterproof models offer up to 51 hours of battery life, while Neuro Sound Technology 2.0 delivers 30% more accurate speech detection in noisy environments. 'Edge AI has redefined what hearing support means for someone like me who is constantly in professional and social settings. Its real-time adaptability across complex environments — from lecture halls to roundtable discussions — has restored not just my ability to hear, but also my confidence to engage fully. For the first time in years, I feel truly connected to the conversations around me. For professionals like me, who rely heavily on communication, this technology is more than a device — it's a lifeline,' said Dr. Mohamed Ali Eltom, Chairman of the International Diabetes Federation for the MENA region and a hearing loss patient. In addition, the device supports a holistic approach to hearing health with tools such as sensor-driven balance assessments, fall detection alerts, and smartwatch integration via the My Starkey mobile app — allowing users to manage hearing settings and track wellness on the go. With hearing loss affecting a growing number of people across the Middle East — including younger individuals exposed to prolonged noise and an ageing population — Starkey MEA is working closely with audiologists and clinics to raise awareness, encourage early screenings, and provide hands-on access to its cutting-edge technology throughout Better Hearing Month. 'Better hearing leads to better living,' added Bechara. 'This month is not only about showcasing our most powerful solution, Edge AI — it's about empowering people to take the first step toward hearing health.'
Khaleej Times
6 days ago
- Khaleej Times
Ferrero Rocher and Raffaello Tablets outperform in groundbreaking indulgence study
As part of their regional launch in the GCC, Ferrero Rocher and Raffaello Tablets, brands synonymous with indulgence, have taken a bold step into the world of science to redefine how we experience indulgence. Their mission? To measure indulgence in numbers, delivering tangible proof of their commitment to sensory delight. In partnership with MyndPlay, pioneers in neuroscience and emotion-tracking technology, Ferrero Rocher and Raffaello Tablets embarked on a groundbreaking study that blended cutting-edge technology with timeless sensory experiences. Using EEG technology, the experiment sought to decode how the human brain reacts to refined sensory stimuli. Participants – including some of the region's most prominent media figures and influencers such as Brianna Fade, Mohammad Ismael, Ahmad Qassem, Jad Chehayeb from Dubai TV, Alanoud Badr, Nirvana Abdul, Maryam Zehi, Mashael Jamal, Rahaf Al Harbi, and Zeynab El Helw – were guided through an immersive exploration of the five senses. Each sense was tested with meticulously curated stimuli: a private violin performance for sound, a golden skyline for sight, soft sand for touch, the rich aroma of oud for smell, and a curated coffee-tasting experience to awaken the palate. With each encounter, the EEG device recorded precise pleasure points, creating a numerical map of indulgence. Once participants had completed these sensory experiences, they were introduced to a new and unexpected indulgence: Ferrero Rocher and Raffaello Tablets. Blindfolded and fitted with EEG headsets, participants first unwrapped, touched, smelled, and finally tasted the creamy, nut-filled Ferrero Rocher and the delicately fragrant, coconut-encrusted Raffaello Tablets. As the blindfolds were removed, they visually absorbed the iconic golden Ferrero Rocher and the radiant, coconut-dusted Raffaello Tablets, marveling at their exquisite presentation. Reactions ranged from quiet awe to enthusiastic praise, with several participants declaring the experience 'unlike anything else.' The findings were clear and conclusive: Ferrero Rocher and Raffaello Tablets delivered the highest peak indulgence scores of any sensory experience tested. With an unprecedented level of prolonged indulgence measured at every step of the sensorial journey, the Tablets outperformed all other stimuli combined. Participants unanimously declared the Tablets as their favorite indulgent experience, with many ranking it far above even their second choice, the live violin performance. This experiment coincides with the launch of Ferrero Rocher and Raffaello Tablets in the GCC, marking a new chapter for the iconic brands. Designed to elevate the chocolate experience, Ferrero Rocher Tablets are available in Original, Dark, and Hazelnut and Almond varieties, while Raffaello Tablets combine white chocolate, coconut, and crunchy almonds. With their blend of textures, aromas, and flavors, these Tablets promise to deliver the most indulgent moments, one bite at a time. Watch the full experience:
